Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report

OBJECTIVE: ROS1 fusions have been identified in 1–2% of non-small-cell lung cancer (NSCLC) patients; they are validated as a driver of carcinogenesis and could be subjected to inhibition by crizotinib. However, previous studies suggested a variable progression-free survival (PFS) ranging from 9.1 to...

Descripción completa

Detalles Bibliográficos
Autores principales: Shu, Yun, Li, Hui, Shang, Hongjuan, Chen, Jun, Su, Xiaoxing, Le, Wei, Lei, Yan, Tao, Liming, Zou, Cailiang, Wu, Wendy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568639/
https://www.ncbi.nlm.nih.gov/pubmed/33116618
http://dx.doi.org/10.2147/OTT.S270961

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568639/
https://www.ncbi.nlm.nih.gov/pubmed/33116618
http://dx.doi.org/10.2147/OTT.S270961

Ejemplares similares